HELP Stock Forecast & Price Target

Helus Pharma is attractive fundamentally because HLP003 has completed enrollment in the Phase 3 APPROACH adjunct MDD study, with topline data due around mid-Nov 2026, creating a clearly defined catalyst around a program already supported by Phase 2 efficacy, including a roughly 13-point placebo-adjusted MADRS improvement and durable effects. Its outlook is further strengthened by HLP004, which showed about a 10-point HAM-A reduction in Phase 2a for GAD, while sector validation, an updated 2026 FDA guidance, and supportive policy and M&A signals reduce regulatory and commercial risk for psychedelic neuropsychiatry. Financially, 2Q26 R&D was $28.9MM, G&A was $13.7MM, cash ended at $157.3MM, and the $50MM financing in June 2026 helps fund operations through the second Phase 3 readout.

Helus Pharma is viewed negatively because its valuation depends on two clinical-stage assets with meaningful execution risk, while HLP003 and HLP004 still face uncertain development paths and regulatory hurdles. Although cash rose to $157.3 million as of March 31 and a $50 million raise closed on June 25, 2026, the model still assumes annual equity raises of $150 million in FY2027E-FY2029E, signaling ongoing dilution risk and funding dependence. The delays to F2029E for HLP003 and F2030E for HLP004, plus the lower assessed asset values and reduced firm value to about $5.6 billion, reinforce a cautious fundamental outlook.